Intracellular Th Stock Total Asset
ITCI Stock | USD 72.00 4.69 6.12% |
Intracellular Th fundamentals help investors to digest information that contributes to Intracellular's financial success or failures. It also enables traders to predict the movement of Intracellular Stock. The fundamental analysis module provides a way to measure Intracellular's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intracellular stock.
Last Reported | Projected for Next Year | ||
Total Assets | 728.3 M | 410.9 M | |
Intangibles To Total Assets | 0.00 | 0.00 |
Intracellular | Total Asset |
Intracellular Th Company Total Asset Analysis
Intracellular's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Intracellular Total Asset | 728.29 M |
Most of Intracellular's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intracellular Th is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Intracellular Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Intracellular is extremely important. It helps to project a fair market value of Intracellular Stock properly, considering its historical fundamentals such as Total Asset. Since Intracellular's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Intracellular's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Intracellular's interrelated accounts and indicators.
Click cells to compare fundamentals
Intracellular Total Asset Historical Pattern
Today, most investors in Intracellular Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Intracellular's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Intracellular total asset as a starting point in their analysis.
Intracellular Total Asset |
Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Competition |
Intracellular Total Assets
Total Assets |
|
Based on the latest financial disclosure, Intracellular Th has a Total Asset of 728.29 M. This is 90.31% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is 97.53% higher than that of the company.
Intracellular Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intracellular's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intracellular could also be used in its relative valuation, which is a method of valuing Intracellular by comparing valuation metrics of similar companies.Intracellular is currently under evaluation in total asset category among related companies.
Intracellular Current Valuation Drivers
We derive many important indicators used in calculating different scores of Intracellular from analyzing Intracellular's financial statements. These drivers represent accounts that assess Intracellular's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Intracellular's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 623.1M | 1.9B | 4.3B | 5.0B | 6.9B | 7.2B | |
Enterprise Value | 568.2M | 1.8B | 4.2B | 4.8B | 6.7B | 7.1B |
Intracellular Institutional Holders
Institutional Holdings refers to the ownership stake in Intracellular that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Intracellular's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Intracellular's value.Shares | Alliancebernstein L.p. | 2023-12-31 | 1.8 M | Franklin Resources Inc | 2023-12-31 | 1.8 M | Wellington Management Company Llp | 2023-12-31 | 1.8 M | Gw&k Investment Management, Llc | 2023-12-31 | 1.6 M | Macquarie Group Ltd | 2023-12-31 | 1.6 M | Clearbridge Advisors, Llc | 2023-12-31 | 1.6 M | Holocene Advisors, Lp | 2023-09-30 | 1.4 M | Pictet Asset Manangement Sa | 2023-12-31 | 1.3 M | T. Rowe Price Associates, Inc. | 2023-12-31 | 1.3 M | Fmr Inc | 2023-12-31 | 11.5 M | Vanguard Group Inc | 2023-12-31 | 9.1 M |
Intracellular Fundamentals
Return On Equity | -0.22 | ||||
Return On Asset | -0.13 | ||||
Profit Margin | (0.30) % | ||||
Operating Margin | (0.26) % | ||||
Current Valuation | 7.25 B | ||||
Shares Outstanding | 96.81 M | ||||
Shares Owned By Insiders | 2.51 % | ||||
Shares Owned By Institutions | 99.05 % | ||||
Number Of Shares Shorted | 3.47 M | ||||
Price To Earning | (6.56) X | ||||
Price To Book | 10.78 X | ||||
Price To Sales | 13.73 X | ||||
Revenue | 462.18 M | ||||
Gross Profit | 95.16 M | ||||
EBITDA | (158.85 M) | ||||
Net Income | (139.67 M) | ||||
Cash And Equivalents | 628.74 M | ||||
Cash Per Share | 6.64 X | ||||
Total Debt | 16.94 M | ||||
Debt To Equity | 0.04 % | ||||
Current Ratio | 9.81 X | ||||
Book Value Per Share | 6.14 X | ||||
Cash Flow From Operations | (124.2 M) | ||||
Short Ratio | 5.29 X | ||||
Earnings Per Share | (1.46) X | ||||
Target Price | 83.77 | ||||
Number Of Employees | 610 | ||||
Beta | 1.01 | ||||
Market Capitalization | 7.78 B | ||||
Total Asset | 728.29 M | ||||
Retained Earnings | (1.62 B) | ||||
Working Capital | 544.25 M | ||||
Current Asset | 541.82 M | ||||
Current Liabilities | 140.69 M | ||||
Net Asset | 728.29 M |
About Intracellular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intracellular Th's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intracellular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intracellular Th based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Intracellular Piotroski F Score and Intracellular Altman Z Score analysis. Note that the Intracellular Th information on this page should be used as a complementary analysis to other Intracellular's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Intracellular's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share 4.843 | Quarterly Revenue Growth 0.503 | Return On Assets (0.13) | Return On Equity (0.22) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.